Omega–3 Fatty Acids, Inflammation and Angiogenesis: Nutrigenomic Effects as an Explanation for Anti-Atherogenic and Anti-Inflammatory Effects of Fish and Fish Oils

Marika Massaro a, b  Egeria Scoditti a, b  Maria Annunziata Carluccio a, b  Maria Rosa Montinari b  Raffaele De Caterina a, c

a CNR Institutes of Clinical Physiology, Pisa and Lecce, b University of Lecce, Ecotekne, Lecce, and c Chair of Cardiology, ‘G. d’Annunzio’ University, Chieti, Italy

Key Words
Omega–3 fatty acids  n–3 fatty acids  Adhesion molecules  Endothelium  Endothelial activation  Atherosclerosis  Cyclooxygenase-2  Plaque angiogenesis  Plaque rupture

Abstract
Atherosclerosis is a dynamic process with inflammatory aspects playing a considerable pathogenetic role. In this process, the vascular endothelium is the key regulator of vascular function, promoting the maintenance of vascular homeostasis or the progression towards vascular disease. In the past 30 years, the dietary intake of omega–3 (n–3) polyunsaturated fatty acids – mainly derived from fish – has emerged as an important way to modify cardiovascular risk through beneficial effects on all stages of atherosclerosis. This review specifically focuses on the modulating effects of n–3 fatty acids on molecular events involved in early and late atherogenesis, including effects on endothelial expression of adhesion molecules, as well as pro-inflammatory and pro-angiogenic enzymes. By accumulating in endothelial membrane phospholipids, omega–3 fatty acids have been shown to decrease the transcriptional activation of several genes through a decreased activation of the nuclear factor-κB system of transcription factors. This occurs secondary to decreased generation of intracellular reactive oxygen species.

Omega–3 fatty acids have recently emerged as an example of nutrients able to modulate the expression of genes involved in inflammation and atherosclerosis. Their ability to influence such processes is therefore a good example of nutrigenomics. This review summarizes the evidence to this regard. Since a description of the molecular events underlying endothelial changes in atherosclerosis is important for an understanding of the mode of action of these nutrients, a short review of current concepts of inflammation and atherosclerosis gives the background to place their genomic effect in context.

Inflammation in Atherosclerosis

Atherosclerosis is currently regarded as a dynamic process arising from functional inflammatory changes in the endothelium of conduit arteries [1]. Here the vascular endothelium, no longer regarded as the passive lining of
blood and lymphatic vessels, is a dynamic organ involved in metacrine, paracrine, and endocrine functions [2]. Located at the interface between the circulation and the vessel wall, the endothelium ‘senses’ changes in hemodynamic forces and blood-borne signals, and reacts by synthesizing and releasing vasoactive substances with anti-thrombotic, vasodilating and anti-atherogenic properties to maintain vascular homeostasis (fig. 1). However, with the persistence of damaging stimuli, such as high blood pressure, high levels of atherogenic lipoproteins, high glucose, high insulin, high homocysteine or products of cigarette smoking, this balance is disrupted and the vasculature, through a dynamic change in the endothelium, becomes susceptible to atheroma formation [3].

In its initial stages, atherosclerosis is characterized by the recruitment, in the wall of conduit arteries, of selected populations of white blood cells, especially monocytes and some T lymphocytes, and, secondly, by the gradual accumulation of lipids and extracellular matrix in the arterial intima, which becomes no longer the virtual space occurring in normal arteries. Monocytes attracted in the intima accumulate lipid droplets first intracellularly (foam cells) and later extracellularly, due to their apoptosis, resulting in the formation of a lipid core. The endothelium and the underlying matrix (fibrous cap) for long time during atherosclerosis progression prevent the content of the highly thrombogenic lipid core from entering in contact with circulating blood. The sudden rupture of this collagen layer, from the outside or, as recently appreciated, from the inside, due to the rupture of vasa vasorum penetrating in the intima or, in a minority of cases, a condition of endothelial erosion, transform this slow process into an acute situation due to the sudden development of thrombosis (fig. 2) [4]. When this occurs in a coronary artery, the ischemic necrosis of the depending myocardium produces the symptoms of an acute coronary syndrome, i.e. acute myocardial infarction or unstable angina.

Since monocyte recruitment into the intima of large arteries is specific for atherosclerosis as compared to other forms of leukocyte-endothelial interactions, it was hypothesized that these localized monocyte-endothelium interactions reflect specific molecular changes in the adhesive properties of the endothelial surface, due to the endothelial surface expression of specific endothelium-leukocyte adhesion molecules (ELAMs) (‘athero-ELAMs’). The first such protein, originally identified in the rabbit hypercholesterolemic model, is vascular cell adhesion molecule (VCAM)-1, a member of the immunoglobulin superfamily. The ligand for VCAM-1 is a heterodimeric integrin receptor, very late antigen 4 (VLA4), whose leukocyte selectivity of expression, on monocytes and lymphocytes, but not on neutrophils, can explain the selectivity of monocyte recruitment in early atherogenesis [5]. Endothelial cells express VCAM-1 early during cholesterol feeding in the rabbit, before the appearance of macrophages/foam cells in the intima of developing fatty streaks, in a temporal pattern consistent with its pathogenetic role in lesion development. Pathophysiologically relevant stimuli for VCAM-1 expression in atherogenesis include minimally oxidized low-density lipoproteins (LDL) or beta-very-low-density lipoproteins (VLDL), the advanced glycation end-products (AGEs) associated with diabetes, and perhaps lipoprotein (Lp)(a), homocysteine, elevated in homocystinuria and in subtler forms of congenital or acquired enzyme defects in homocysteine biosynthetic pathways, and possibly also high glucose and high insulin, occurring in diabetes and insulin resistance, respectively. In addition to these humoral stimuli, the endothelial gene expression of VCAM-1 also responds to hemodynamic forces, potentially explaining the localization of atherosclerosis in particular sites of

---

Fig. 1. Endothelial homeostatic derangements in atherosclerosis. Endothelium-derived factors act in concert to appropriately control vasoconstriction, smooth muscle proliferation, thrombosis, inflammation, coagulation and fibrinolysis. Endothelial dysfunctions, defined as the loss of any of these balanced functions, promote atherosclerosis. NO = Nitric oxide; PGI₂ = prostacyclin; EDHF = endothelium-derived hyperpolarizing factor; tPA = tissue-type plasminogen activator; EPCR = endothelial cell protein C receptor; IL-8 = interleukin-8; MCP-1 = monocyte chemoattractant protein-1; ET-1 = endothelin-1; Ang II = angiotensin II; TAFI = thrombin-activatable fibrinolysis inhibitor; PAF = platelet activating factor; PAI-1 = plasminogen activator inhibitor-1; ICAM-1 = intercellular adhesion molecule-1; VCAM-1 = vascular cell adhesion molecule-1; VEGF = vascular endothelial growth factor.

---

Nutrigenomics of Omega–3 Fatty Acids
the arterial vasculature (for a general review on these issues, see [6]). A causal role of VCAM-1 in atherosclerosis is shown by the fact that the expression of a hypomorphic variant of VCAM-1, due to a partial knock-out of the molecule, protects against atherosclerosis in the LDL receptor knockout mouse model [7].

Once adhered, monocytes transmigrate, through the action of chemotactic stimuli also deriving from the activated endothelium, into the intima, the innermost layer of the arterial wall, where, upon internalization of modified lipoproteins, they become macrophages able to secrete proinflammatory cytokines, which contribute to maintaining a state of vascular inflammation, further
augmenting the expression of adhesion molecules, chemotactants and macrophage-activating factors, thus initiating a vicious circle leading to lesion progression (fig. 2). Later on, the production of matrix metalloproteinases (MMP) by the same macrophages as well as by endothelial cells may promote the erosion of the collagen layer of the fibrous plaque and ultimately lead to plaque rupture (fig. 2) [8].

Stability of the atherosclerotic plaque is indeed thought to reflect the balance and interplay of various dynamic factors, including endothelial dysfunction, the proliferation of smooth muscle cells (SMC), which are mainly responsible for the synthesis of collagen, and the degradation of collagen and other elements of the extracellular matrix by MMP.

The much sought-after prevention of acute coronary events requires therefore interventions that affect such cellular and molecular mechanisms leading to the slow formation of atherosclerotic lesions, as well as precipitating plaque rupture.

**Inflammatory Angiogenesis as a Promoter of Plaque Growth and Instability**

An increasing body of experimental and pathology data suggests that angiogenesis – the sprouting of new capillaries from pre-existing blood vessels (fig. 3) – may contribute to the initiation and progression of atherosclerosis [9]. The adventitial layer of human arteries normal-
ly contains a microvascular network, termed vasa vasorum, that delivers oxygen and nutrients to the outer layers of the arterial wall. In contrast to the adventitia and, occasionally, the outer media, the inner media and the intima of normal large arteries usually do not contain capillaries [10, 11]. However, during the progression of atherosclerosis, largely immature neo-microvessels penetrate into the media and the thickened intima (fig. 2) in more than 40% of lesions, initially stimulated by local hypoxia and then instigated by the inflammatory processes within the plaque [10, 11]. The possibility that such neovascularization plays a role in plaque growth and destabilization was first hypothesized by Winternitz et al. [12] and Geiringer [13] in the late 1930s and 1940s, respectively, and partially demonstrated by Barger et al. [14] in the mid-1980s through the finding that 'plaque malignant neovascularization' in atherosclerotic coronary artery segments preferentially originates from the adventitial vasa vasorum, contrary to the intima of healthy segments of the same vessel, where there is no apparent angiogenesis. Later on, several reports have pointed out that plaque neo-angiogenesis might contribute to plaque instability, showing a positive association between the neovascularization in the intima and the media on the one hand, and symptomatic carotid occlusive disease on the other [15, 16], as well as between the density of coronary adventitial vessels reaching the intima and the extent of lumen stenosis [17]. Furthermore, it has been recently reported that the number of vasa vasorum is increased up to 2-fold in vulnerable plaques and up to 4-fold in ruptured plaques compared with stable plaques with severe luminal narrowing [18]. The entrance of neo-vessels into the intimal space from the adventitia occurs specifically at breakpoints in the medial layer, below sites of early necrotic core formation, following a typical maturation sequence: the neo-vessels first divide as they approach the core with secondary and tertiary branches, but while microvessels close to the medial wall are well formed, being accompanied by surrounding SMC, the intimal vessels near the lumen appear immature and therefore less functional, being too small to conduct adequate blood flow to ischemic tissues, and more prone to rupture [18]. A similar pattern occurs in the vessels of proliferative diabetic retinopathy, where the intimal vessels are mechanically weak and more prone to bleed [19]. Since these weak microvessels are often accompanied in their development by a recruitment of T helper cells [20], it has been also hypothesized that the T cells release of interferon (IFN)-γ may inhibit SMC proliferation and therefore actively contribute to the absence of SMC in proliferating neovessels [21]. Furthermore, their augmented expression of endothelial leukocyte adhesion molecules suggests that they may actively recruit inflammatory cells into the lesions [22, 23], thus allowing the establishment of a positive feedback loop whereby inflammatory cells stimulate plaque angiogenesis, and new vessels promote further recruitment of inflammatory cells.

That these microvessels are functionally important in atherogenesis and its complications is also illustrated by the ability of angiogenesis inhibitors, such as angiostatin and TNP-470, to reduce angiogenesis and inhibit the development of lesions in apoE knockout mice [24], as well as by the observation that a classical pro-angiogenic stimulus, such as vascular endothelial growth factor (VEGF), potently promotes lesion development [25, 26].

**Role of COX-2 as Potential Regulator of Inflammatory Angiogenesis and Plaque Instability**

Due to the ability of prostanoids to orchestrate the complex neovascularization process [27], the proinflammatory enzyme cyclooxygenase (COX)-2 is now regarded as a critical inducer of angiogenesis [28]. Prostanoids include prostaglandin (PG)D2, PGF2α, prostaoyclin (PGI2), and thromboxane (TX) A2, and their biosynthesis involves 3 sequential enzyme-catalyzed steps (fig. 4): (1) agonist-induced phospholipase catalyzed activation, leading to the release of arachidonic acid from membrane phospholipid pools; (2) cyclooxygenase (COX)-catalyzed oxygenation of the free fatty acid to generate the cyclic endoperoxide PGH2, and (3) enzymatic rearrangement of PGH2 structure to yield one of several bioactive derivatives. While the first 2 steps are shared by virtually all human cell types, the expression of downstream prostanoid synthases displays considerable cell type specificity [29].

Prostanoids mediate angiogenesis through multiple mechanisms (fig. 4) including: (1) the induction of VEGF production [30]; (2) the stimulation of endothelial cell sprouting, migration and tube formation [31–33]; (3) the enhancement of endothelial cell survival, through the upregulation of the anti-apoptotic protein B cell lymphoma (Bcl)-2 [34] and the activation of phosphatidylinositol (PI)3-kinase (K)-Akt pathway [35, 36]; (4) the upregulation of MMP-2 [37, 38] and MMP-9 [39], which are required for vascular invasion; (5) the promotion of angiogenic functions of the α,β integrin [40, 41]; (6) the activation of the epidermal growth factor receptor (EGFR), causing downstream angiogenic events [42], and (7) the decreased production of the endogenous angiogenesis inhibitor interleukin (IL)-12 [43].
Several reports have demonstrated the presence of both mRNA and protein for COX-2 in macrophages and SMC of atherosclerotic plaques, as well as of COX-1 and COX-2 in the endothelium of both atherosclerotic and healthy vessels [44, 45], thus suggesting a potential patho-
genetic role for COX-2 activity. Furthermore, the finding of a co-localization of COX-2, MMP-9 and membrane type (MT)-1 MMP in the endothelial lining of vasa vasorum in human atherosclerotic aortas suggests a COX-2-mediated promotion of plaque angiogenesis [46].

Besides contributing to plaque neovascularization [47], several other mechanisms have been hypothesized by which COX-2 inhibition may prevent atherothrombosis. COX-2 directly contributes to plaque instability, favoring the MMP release in macrophages, as observed in vitro [48] and in vivo in atherosclerotic lesions obtained from patients with symptomatic carotid artery disease, where the simultaneous overexpression of functionally coupled COX-2, PGE synthase and MMP has been reported [49]. Secondly, prostaglandins exert potent actions on vascular SMC, regulating contractility [50, 51], cholesterol metabolism [52], and proliferation [53]. The increased expression of COX-2 may thus contribute to the accumulation of lipids in lesional SMC, besides macrophages, favoring the formation of SMC and macrophage-derived foam cells within the atheroma. Conversely, anti-proliferative and anti-migratory actions of COX-2 products on SMC [53] contribute to the evolution of a lesion toward a SMC-depleted and macrophage-enriched plaque phenotype, and thus a more vulnerable plaque [54].

In spite of these well-documented pro-atherogenic functions [55], the usefulness to inhibit COX-2 activity is still controversial [56]. In murine models of atherosclerosis, treatment with selective COX-2 inhibitors has been reported to decrease, increase or have no impact on atherosclerosis [57–61]. These studies suggest that the role of COX-2 in atherosclerosis is complex and may vary with lesion stage or the animal model. A critical review of the experimental design of the studies so far reported reveals several plausible explanations for the variability of the results. Studies reporting a beneficial effect of selective COX-2 inhibition on atherosclerosis mostly looked at the impact of treatment on early atherosclerotic lesion formation, whereas studies showing no effect evaluated the impact on advanced lesions. Thus, one can hypothesize that COX-2 contribution in atherogenesis varies temporarily according to the stage of atherosclerotic lesion formation.

Fig. 4. COX-2 induces angiogenesis via multiple pathways. COX-2 converts arachidonic acid to prostaglandin H$_2$ (PGH$_2$), which is then converted to thromboxane A$_2$ (TXA$_2$), prostaglandin E$_2$ (PGE$_2$), prostacyclin (PGI$_2$), prostaglandin D$_2$ (PGD$_2$) and prostaglandin F$_2\alpha$ (PGF$_2\alpha$) by tissue-specific prostanoid synthases. Each prostanoid promotes specific angiogenic steps and mediators. References specific to each mechanism depicted are reported in parentheses. EC = Endothelial cell(s); VEGF = vascular endothelial growth factor; α,β = vascular integrin; MMP = matrix metalloproteinase; Bcl-2 = B-cell lymphoma-2, an antiapoptotic factor; Akt/protein kinase (PK)B = a survival signal pathway; c-fos = a proto-oncogene.

Cardiovascular Protection by Omega–3 Fatty Acids

Omega–3 Fatty Acids: Structure, Source and Metabolism

Polyunsaturated fatty acids (PUFA) are organic acids naturally containing more that one double bonds in their aliphatic chain. It is the number and position of double bonds within the hydrocarbon chain that gives PUFA their name and their physical and physiological properties. Biologically relevant families of PUFA are the omega–3 and the omega–6 fatty acids. In the omega–3 fatty acids the terminal double bond is on the third carbon (from the methyl end of the hydrocarbon chain, fig. 5). In this respect, they are structurally distinct from the more commonly encountered omega–6 family in which the terminal double bond is on the sixth carbon. The simplest members of omega–6 and omega–3 families are linoleic (18:2n–6) and ω-linolenic (18:3n–3) acids, respectively (fig. 5). Since the double bond in the n–3 or n–6 position cannot be inserted into fatty acids by animal enzymes (but only by vegetable Δ12- and Δ15-desaturases), linoleic and ω-linolenic acids represent ‘essential nutrients’ for mammals, as was shown in the late 1920s when omega–3

Nutrigenomics of Omega–3 Fatty Acids

J Nutrigenet Nutrigenomics 2008;1:4–23
and omega–6 deprivation experiments performed in rats identified the ‘essential fatty acid deficiency' syndrome as similar to other ‘essential nutrient deficiencies' syndromes [62, 63]. It is estimated that minimum human requirements for these fatty acids are 1 and 0.2% of daily energy intake for omega–6 and omega–3 fatty acids, respectively [64]. Because they are synthesized by plants, plant tissues and oils are good sources of linoleic and α-linolenic acids. Green plant tissues are especially rich in α-linolenic acid, which typically comprises 55% of the fatty acids present in green vegetables. However, such tissues are not rich in fat, and therefore this source does not make a sufficient contribution to the minimum intake of this fatty acid in humans. In contrast, some plant oils such as corn, sunflower and rapeseed oil, can make a significant contribution to the intakes of these fatty acids and of their longer derivatives. In fact, although mammalian cells cannot synthesize linoleic and α-linolenic acids, they can metabolize them by further desaturation and elongation (fig. 5). Linoleic acid can be converted into γ-linolenic acid (18:3n–6) by Δ6-desaturase and then γ-linolenic acid can be elongated (by elongase) to dihomo-γ-linolenic acid (20:3n–6). Dihomo-γ-linolenic acid can be desaturated further by Δ5-desaturase to finally yield arachidonic acid (20:4n–6). Using the same series of enzymes, α-linolenic acid is converted into eicosapentaenoic acid (20:5n–3, EPA) (fig. 5). The further conversion of EPA into docosahexaenoic acid (22:6n–3, DHA) involves a first addition of two carbon atoms to form docosapentaenoic acid (22:5n–3, DPA), two further carbons to produce 24:5n–3, and a desaturation to form 24:6n–3. The removal of two carbons from 24:6n–3, by limited β-oxidation, yields DHA [65].

In mammals, these pathways of desaturation and elongation occur mainly in the liver, where Δ6-desaturase constitutes the rate-limiting enzyme [66]. The preferred substrate for Δ6-desaturase is α-linolenic acid [66]; however, being linoleic acid much more prevalent than α-linolenic acid in most human diets, metabolism of n–6 fatty acids is quantitatively more important. Furthermore, recent studies have revealed that the conversion of α-linolenic acid into its longer-chain derivatives is, altogether, scarcely efficient in adult humans, especially in males [67, 68]. This means that the direct intake of the long-chain derivatives EPA and DHA is by far the easiest way to increase the concentration of such fatty acids in human tissues.

A good dietary source of long-chain n–3 fatty acids is fish. Fish can be classified into ‘lean' fish, that store fat as triacylglycerols in the flesh (e.g., cod), or ‘fatty' fish that store fat as triacylglycerols in the flesh (e.g., mackerel, herring, salmon and tuna). The oil obtained from the flesh of fatty fish or the liver of lean fish is termed ‘fish oil', and has the distinctive characteristic of being rich in long-chain omega–3 fatty acids. Different oily fish (and therefore different fish oils) contain different amounts of EPA and DHA (table 1), and this seems to be related to the dietary habits and metabolic characteristics [69, 70].

Table 1. EPA and DHA contents of various seafood and other foods [from refs. 145, 146]

<table>
<thead>
<tr>
<th>Food</th>
<th>EPA, g/100 g</th>
<th>DHA, g/100 g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cod</td>
<td>0.08</td>
<td>0.01</td>
</tr>
<tr>
<td>Trout</td>
<td>0.23</td>
<td>0.09</td>
</tr>
<tr>
<td>Plaice</td>
<td>0.16</td>
<td>0.04</td>
</tr>
<tr>
<td>Canned crab</td>
<td>0.47</td>
<td>0.08</td>
</tr>
<tr>
<td>Haddock</td>
<td>0.05</td>
<td>0.01</td>
</tr>
<tr>
<td>Herring</td>
<td>0.51</td>
<td>0.11</td>
</tr>
<tr>
<td>Mackerel</td>
<td>0.71</td>
<td>0.12</td>
</tr>
<tr>
<td>Prawns</td>
<td>0.06</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Mussels</td>
<td>0.41</td>
<td>0.02</td>
</tr>
<tr>
<td>Canned sardines</td>
<td>0.89</td>
<td>0.10</td>
</tr>
<tr>
<td>Salmon</td>
<td>0.50</td>
<td>0.40</td>
</tr>
<tr>
<td>Roast beef</td>
<td>0.02</td>
<td>0.02</td>
</tr>
<tr>
<td>Roast lamb</td>
<td>0.03</td>
<td>0.04</td>
</tr>
<tr>
<td>Roast pork</td>
<td>0.01</td>
<td>0.02</td>
</tr>
<tr>
<td>Chicken</td>
<td>0.01</td>
<td>0.02</td>
</tr>
<tr>
<td>Venison</td>
<td>0.04</td>
<td>0.09</td>
</tr>
</tbody>
</table>
Epidemiologic and Experimental Evidence for Atheroprotective Effects of Omega–3 Fatty Acids

Over the past three decades, a great deal of epidemiologic evidence has been accumulated supporting cardiovascular benefits of fish and fish oil intakes [72]. Historically, first observations were done in Greenland, Northern Canada and Alaska, where Inuit populations on traditional dietary habits showed much lower-than-predicted cardiovascular mortality, despite their high fat intake [73–75]. The protective component was suggested to be the omega–3 fatty acids consumed in very high amounts (5–15 g/day) as a result of the regular intake of fish or fish-eating mammals, such as seals [76]. Afterwards, similar observations were done also for Eastern populations such as the Japanese [77] and the Chinese [78] consuming traditional diets rich in oily fish. In Western populations with a generally low intake of omega–3 fatty acids, both protective effects [79–83] and no effects [84–87] of omega–3 fatty acids on cardiovascular disease have been reported. This can be explained by the difficulty in maintaining constant feeding habits in a population during long observational studies and by the competing influence of other dietary principles, including saturated or other unsaturated fatty acids.

The epidemiologic association between dietary omega–3 fatty acids and protection from cardiovascular disease can be attributed, at least in part, to a decreased extent of atherosclerosis. Many experimental studies have clearly demonstrated that omega–3 fatty acids favorably affect many of the factors involved in the development of atherosclerosis (table 2). Numerous animal studies have shown decreased atherosclerosis in animals treated with omega–3 fatty acids (reviewed in [88–90]). Furthermore, evidence has been obtained about such effects in humans, through autopsy studies in Alaskan natives (consuming high amounts of fish-derived products) and non-natives, mostly consuming Western-type diets. In the study by Newman et al. [75], the magnitude of difference in fatty streak development appears larger in younger age groups, suggesting an effect of diet mainly in the early events leading to fully developed atherosclerotic lesions. Furthermore, a study of omega–3 fatty acids supplementation after coronary bypass surgery indicated that such treatment significantly reduces vein graft stenosis [91], a process which may be regarded as an accelerated form of atherosclerosis.

Table 2. Effects of omega–3 polyunsaturated (PUFA) fatty acids on factors involved in the development of atherosclerosis

<table>
<thead>
<tr>
<th>Pro-atherosclerotic factor</th>
<th>Effect of omega–3 PUFA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma triacylglycerol concentration (fasting and postprandial)</td>
<td>↓</td>
</tr>
<tr>
<td>Production of chemoattractants</td>
<td>↓</td>
</tr>
<tr>
<td>Production of growth factors</td>
<td>↓</td>
</tr>
<tr>
<td>Cell surface expression of adhesion molecules</td>
<td>↓</td>
</tr>
<tr>
<td>Production of cytokines</td>
<td>↓</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>↓</td>
</tr>
<tr>
<td>Endothelial relaxation</td>
<td>↑</td>
</tr>
<tr>
<td>Thrombosis</td>
<td>↓</td>
</tr>
<tr>
<td>Cardiac arrhythmias</td>
<td>↓</td>
</tr>
<tr>
<td>Atherosclerotic plaque stability</td>
<td>↑</td>
</tr>
</tbody>
</table>

Modulation of Endothelial-Leukocyte Interactions and Endothelial Activation by Omega–3 Fatty Acids

Our own research has disclosed potential mechanistic explanations for the preventive or therapeutic use of omega–3 fatty acids. We hypothesized that omega–3 fatty acids modulate atherogenesis by affecting processes of early atherosclerotic development leading to the formation of fatty streaks. As illustrated above, such processes are mostly comprised under the name of 'endothelial activation'. We used human adult saphenous vein endothelial cells or human umbilical vein endothelial cells activated by cytokines, as an in vitro model of these early steps in atherogenesis, first assessing the effects of various fatty acids on the surface expression of endothelial leukocyte adhesion molecules, and subsequently characterizing mechanisms and functional relevance of such effects. In particular, we observed that DHA, when added to cultured endothelial cells hours to days before the stimulation with cytokines, early enough to allow a significant incorporation in cell membrane phospholipids, significantly inhibited events connected with endothelial activation, including the expression of adhesion molecules such as VCAM-1, E-selectin and, to a lesser extent, ICAM-1, after stimulation with virtually any stimulus able to elicit the coordinated expression of such genes [6, 92]. The inhibition of adhesion molecule expression occurred in a range of DHA concentrations compatible with nutritional supplementation of this fatty acid to a normal Western diet, occurred at any time point after the appearance of cytokine effect, modifying the kinetics of surface expression of adhesion molecules, and was strictly related in magnitude to the extent of incorporation into total cell

Nutrigenomics of Omega–3 Fatty Acids
lipids. Indeed, the extent of VCAM-1 inhibitory effect paralleled the incorporation of DHA in cellular phospholipids, and was inversely related to the content of omega-6 fatty acids [6, 92]. This effect was not limited to the expression of transmembrane molecules involved in leukocyte recruitment, but appeared to occur also for other cytokine-activated products, such as the soluble proteins IL-6 and IL-8, involved in the amplification of the inflammatory response (IL-6), or in the specific chemotraction for granulocytes (IL-8), and was accompanied by a functional counterpart, i.e., a reduced monocyte or monocytoid cell adhesion to cytokine-activated endothelium [6, 92].

Experiments following the fate of 14C-labelled DHA into cell phospholipids showed a significant incorporation of DHA into the phosphatidyl ethanolamine pool, i.e., in a specific and not particularly abundant phospholipid pool, likely in the inner plasma membrane, and therefore in a possibly strategic position to alter intracellular signal transduction pathways. To investigate the mechanism of DHA action on endothelial activation, we analyzed the effects of various fatty acids (differing in chain length, number, position – omega-3 vs. omega-6 vs. omega-9 – and cis/trans configuration of the double bonds) on the stimulated expression of VCAM-1. We observed the lack of any effect by saturated fatty acids, and an increase of potency of PUFA in parallel with the number of unsaturations, independently of the chain length and configuration (cis vs. trans) of the double bond [93]. In the same experimental conditions we also measured the intracellular cytokine-induced production of reactive oxygen species (ROS) believed to act as critical second messengers in the signaling pathway leading to the activation of adhesion molecule expression and hence to endothelial activation. In parallel with the modulation of VCAM-1 expression, a reduction of intracellular ROS release was also evident, proportional to the number of double bonds in the fatty acid chain [94]. This suggested that a property related to fatty acid peroxidability (the presence of multiple double bonds), usually regarded as a detrimental consequence of PUFA enrichment of cell membranes, is probably also directly related to the inhibition of ROS release/production, an event crucial for cell responsiveness to cytokines. Whether, however, PUFA protective effects occur through a direct quenching of free ROS on the double bonds or indirectly through the production of metabolically active oxidized products is still a matter of debate.

These data are not in contrast with the possibility that a product of omega-3 fatty acid oxidation inhibits cytokine-induced VCAM-1 expression through a peroxisome proliferators activated receptor-α (PPARα)-dependent mechanism, as observed by Sethi et al. [95]. PPARs are ligand-activated transcription factors belonging to the nuclear receptor superfamily, which also includes the steroid and thyroid hormone receptors [96]. Originally cloned in an attempt to identify the molecular mediators of peroxisome proliferation in the liver of rodents [97], after their identification also in endothelial cells [98] many experimental data have accumulated regarding their function as regulators of lipid and glucose metabolism and of inflammatory gene expression in vascular cells [96, 99]. The PPAR family is comprised of three members, α, γ and β/δ. PPARγ is found in tissues where fatty acid catabolism is important (the liver, the kidney, the heart, and the muscle), and regulates genes that are involved in lipid and lipoprotein metabolism [100]. PPARα natural ligands include polyunsaturated fatty acids (DHA and EPA), oxidized phospholipids, lipoprotein lipolytic products and synthetic ligands such as fenofibrate and gemfibrozil clinically used to treat patients with elevated serum triglycerides [101]. PPARγ, conversely, controls adipocyte differentiation and lipid storage [102]. PPARγ natural ligands are the prostaglandin D2 derivative 15-deoxy-Δ12,14-prostaglandin J2 and forms of oxidized linoleic acid, 9- and 13(S)-hydroxyoctadecadienoic acid (HODE). PPARβ/δ is expressed in many tissues and like PPARα plays a role in lipid metabolism by stimulating fatty acid oxidation in the heart and the skeletal muscle [103]. It is known that synthetic PPARα agonists decrease the transcription of VCAM-1 and the adhesion of monocytes to cytokine-activated endothelial cells [104]. Sethi and coworkers [105] observed that oxidized EPA, activating PPARα, reduces cytokine- and LPS-induced NF-κB activation, VCAM-1 expression and the adhesion of monocytes in vivo. This effect was seen to occur in a PPARα-dependent fashion because oxidized EPA did not show any effect in LPS-treated PPARα-deficient mice [95].

Modulation of Inflammatory Angiogenesis and Plaque Stability by Omega-3 Fatty Acids

A recent study has disclosed a further potential role for omega-3 fatty acids in promoting a decrease in the risk of atherosclerotic plaques rupture in patients awaiting carotid endarterectomy [106]. In this study, plaques from patients taking fish oil featured a clear incorporation of omega-3 fatty acids into plaque lipids, and this correlated with a reduced macrophage infiltration and thicker fibrous caps compared with plaques from pa-
tients assuming sunflower oil-enriched control capsules [106]. In the attempt to find out the mechanistic basis of such plaque-stabilizing effect, an anti-angiogenic activity as well as a reduction of MMP release by omega–3 fatty acids might well be invoked. We specifically looked at the effects of omega–3 fatty acids on angiogenesis and MMP expression in atherosclerosis. Studies of this kind are found in the literature in the area of cancer and tumor angiogenesis, from which a number of paradigms are more and more nowadays transferred to cardiovascular medicine [9]. In the early 1990s, Rose and Connolly found that dietary omega–3 fatty acids inhibited the growth and development of metastases from transplanted MDA-MB-435 human breast cancer cells in the athymic nude mice [107]. The invasive potential of these cells, when evaluated in vitro, also appeared to be reduced when the cells were incubated with EPA and DHA [108]. The same authors subsequently expanded these results showing that the effect of DHA on tumor growth could be explained by the reduction of tumor angiogenesis (microvessel count) and the production of PGE₂, known to affect the release of MMP [109]. In this study, the release of MMP was not assessed, but using similar cancer cell transplantation in the nude mice model, Suzuki et al. [110] later showed that the inhibition of lung metastases of a colon cancer cell line by EPA and DHA was associated with a reduced activity of MMP-9. Such a reduction in MMP-9 activity was also found by Harris et al. [111] in the uterus, the placenta and the liver of rats fed diets enriched with DHA. These authors explained their findings according to the known competition hypothesis of omega–3 fatty acids with omega–6 fatty acids (mostly arachidonic acid) for being substrates for cyclooxygenase. This would have consequently changed the production of PGE₂, thus in turn affecting MMP activity. Omega–3 fatty acids also negatively affect angiogenesis reducing the tumor production of VEGF [112] and the endothelial expression of the VEGF receptor Flk-1 [113].

The in vivo anti-angiogenic activity of omega–3 fatty acids has been confirmed in in vitro models of angiogenesis by Kanayasu et al. [114] and Tsuji et al. [115], who separately tested bovine carotid artery endothelial cells treated with omega–3 fatty acids in different angiogenesis models. Similar results were confirmed in our laboratory using human umbilical vein endothelial cells (HUVEC). By performing ‘Matrigel’ assays, which allow to detect the formation of capillaries in a tri-dimensional collagen matrix, we observed that the exposure of HUVEC to DHA reduced the vascular endothelial tube-like formation induced by VEGF and phorbol-myristate acetate (PMA), as determined by the reduced number of branching points formed by DHA-treated HUVEC on the matrix surface (fig. 6). In agreement with what ob-

**Fig. 6.** DHA inhibits endothelial cell tube formation. Human umbilical vein endothelial cells (HUVEC) were treated with 25 μmol/l docosahexaenoic acid (DHA) for 48 h and, after enzymatic detachment, plated on Matrigel-coated 48-well plates and stimulated with 20 ng/ml vascular endothelial growth factor (VEGF) plus 10 ng/ml phorbol myristate acetate (PMA). After incubation at 37°C for 4 h, cells showed tube formation. The quantification of tube formation was done by counting the number of branching points in microscopic photographs. The bar graph represents data from 3 independent experiments with two wells per condition and 2–3 fields per well. * p<0.05 vs. stimulated control.
COX-2 Gene Expression: A Pivotal Role for NF-κB

There are two known isoforms of COX, COX-1 and -2. The gene for COX-1, located on human chromosome 9, is approximately 22 kb in length with 11 exons, and is transcribed as a 2.8 kb mRNA. COX-1 is a glycoprotein of 576 amino acids with an apparent molecular mass of 69 kDa (table 3). There are several putative transcriptional regulatory elements in the promoter region, including two Sp1 motifs, two activator protein (AP)-2 sites, a nuclear factor for interleukin-6 (NF-IL-6) motif, and a GATA site, but clearly shown by studies using deleted and site-mutated promoter constructs [118]. Active NF-κB complexes are dimers of various combinations of the Rel family polypeptides consisting of p50 (NF-κB1), p52 (NF-κB2), c-Rel, v-Rel, Rel A (p65), and Rel B [122]. In resting cells, NF-κB is retained in the cytoplasm by binding to one of the inhibitory IκB proteins (IκBα, IκBβ, IκBe, p105, and p100), which blocks the nuclear translocation of NF-κB [122]. NF-κB is activated in response to a wide variety of pro-inflammatory and pro-angiogenic stimuli each promoting the dissociation of IκB through its phosphorylation, followed by ubiquitination and degradation (fig. 7). Thus, the unmasking of the nuclear localization sequence of NF-κB allows NF-κB to enter the nucleus and bind to κB-regulatory elements [121]. The phosphorylation of IκB is catalyzed by an IκB kinase (IKK) complex [122].

Table 3. Comparison of COX-1 and COX-2

<table>
<thead>
<tr>
<th></th>
<th>COX-1</th>
<th>COX-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Locus</td>
<td>9q32–q33.3</td>
<td>1q25.2–q25.3</td>
</tr>
<tr>
<td>Size of gene</td>
<td>22 kb</td>
<td>8.3 kb</td>
</tr>
<tr>
<td>Number of exons</td>
<td>11</td>
<td>10</td>
</tr>
<tr>
<td>Size of mRNA</td>
<td>2.8 kb</td>
<td>4.6 kb</td>
</tr>
<tr>
<td>Coding nucleotides</td>
<td>1,797</td>
<td>1,812</td>
</tr>
<tr>
<td>Number of amino acids</td>
<td>576</td>
<td>604</td>
</tr>
<tr>
<td>5’-Flanking region</td>
<td>no TATA box, GC-rich, Sp-1</td>
<td>NF-κB, NF-IL-6, AP-2, CRE, TATA box</td>
</tr>
<tr>
<td>3’-Untranslated region</td>
<td>0.7 kb</td>
<td>2 kb, AUUUA-rich elements</td>
</tr>
<tr>
<td>Style of expression</td>
<td>constitutive</td>
<td>inducible</td>
</tr>
<tr>
<td>Size of protein</td>
<td>69 kDa</td>
<td>71 kDa</td>
</tr>
</tbody>
</table>

served by Jones et al. [116], we also observed an anti-angiogenic effect after cell treatment with NS-398, an inhibitor of COX-2 activity, thus further supporting the hypothesis of a pro-angiogenic role of COX-2 metabolites. This made the hypothesis plausible that DHA might exert an anti-angiogenic effect also reducing COX-2 expression.

sequence analysis of the 5’-flanking region has shown several potential transcription regulatory elements, including a TATA box, a nuclear factor (NF)-IL-6 motif, two AP-2 sites, three Sp1 sites, two NF-κB sites and a cyclic adenosine mono-phosphate response element (CRE) (fig. 6). However, only a limited number of elements, the CRE, the NF-IL-6 and the NF-κB, are known to be critically involved in the regulation of the endothelial COX-2 gene expression [118].

NF-κB comprises a family of redox-sensitive transcription factors recognized as critical regulators of the expression of many pro-inflammatory genes, such as those encoding for adhesion molecules (VCAM-1, ICAM-1 and E-selectin), chemokines, cytokines, and enzymes producing inflammatory mediators, such as COX-2 [121]. Sequencing of the endothelial COX-2 promoter region has revealed the presence of two NF-κB consensus sites [118], and their importance in COX-2 induction has been clearly shown by studies using deleted and site-mutated promoter constructs [118].
The core of IKK complex consists of a heterodimer of IKK\(\alpha\) and IKK\(\beta\), and two IKK-\(\gamma\) subunits. IKK\(\alpha\) and IKK\(\beta\) mediate the phosphorylation of I\(\kappa\)B, whereas IKK-\(\gamma\) links the core to the upstream signaling molecules (fig. 7) [122]. Also the activation of the IKK complex is dependent on phosphorylation, and multiple upstream kinases, some of which are redox-sensitive, have been suggested to act as IKK kinases [122].

Many agents that activate mitogen-activated protein kinases (MAPK) also induce an overproduction of ROS besides activating NF-\(\kappa\)B, suggesting a cross-talk between these pathways (fig. 7). For example, IL-1 has been shown to induce COX-2 through a mechanism mediated by the activation of the extracellular signal-regulated kinases (ERKs), C-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38 MAPK [123]. Lysophosphatidylcholine, a component of oxidized LDL, activates COX-2 expression by p38 MAPK kinase activation, the proangiogenic transcription factors cAMP-responsive element-binding protein (CREB) and activating transcription factor (ATF)-1 [124]. Finally, phorbol myristate acetate (PMA), an activator of protein kinase C (PKC), induces COX-2 primarily through the activation of ERK1/2 [125]. However, the exact site of interference of
these MAPK activities along the pathway leading to NF-κB activation, as well as the site of interference with ROS production, likely triggered by the activation of nicotinamide adenine dinucleotide (phosphate) [NAD(P)H] oxidase (fig. 7 and 8), is still elusive.

**Effects of Omega-3 Fatty Acids on Endothelial COX-2 Expression**

The effect of omega-3 fatty acids on COX-2 expression and activity in the vascular tissue has not been extensively studied, and the findings are not always in agreement. In the murine monocyte cell line RAW264.7, DHA [126, 127], but not EPA [128], reduced the stimulated COX-2 expression. Similarly, results obtained using cultured endothelial cells have been variable. Gilbert et al. [129] showed that DHA treatment of bovine aortic endothelial cells potentiated COX-2 expression induced by PMA. Conversely EPA, but not DHA, greatly decreased IL-1β-induced COX-2 expression in human microvascular endothelial cells [130]. Using both human saphenous and umbilical vein endothelial cells (HSVEC and HUVEC, respectively), we have recently observed that DHA treatment before IL-1 or PMA stimulation reduces COX-2 expression (see fig. 9a) and activity [131]. The reg-

---

*Fig. 8.* A putative scheme of the NAD(P)H oxidase system in the vascular endothelium. Endothelial NAD(P)H oxidase is composed of a membrane-bound component and a cytosolic moiety, gp91^phox^ (where phox is phagocyte oxidase) – also named Nox2 (where NOX is NADPH oxidase) – and p22^phox^ are joined to form cytochrome b$_{558}$ and, together with the low-molecular-weight protein Rap1A, are located across the plasma membrane. The cytosolic components are p40^phox^, p47^phox^, p67^phox^, and Rac2. All the cytosolic subunits join the membrane-bound element when they are activated. The arrows indicate the protein-protein interactions among NAD(P)H oxidase components in the inactive and active states. During activation, one of the two SH3 domains of p47^phox^ binds to a proline-rich sequence within the C-terminus of p22^phox^. The other SH3 domain binds to a proline-rich sequence in p67^phox^. Moreover, the SH3 domain in the C-terminus of p67^phox^ binds to a proline-rich sequence of the p47^phox^. P67^phox^ contains a binding region for Rac, and p40^phox^ can interact with the C-terminal proline-rich domain of p47^phox^.

The endothelial enzyme seems to be distributed for the 50% on plasma membrane and for the remaining 50% in a perinuclear position [141].
ulation of COX-2 expression involves both transcriptional and post-transcriptional events. Post-transcriptional regulation of COX-2 is dependent, in part, on ‘UAAAU’ instability sequences contained within the 3’-untranslated region (UTR) of the encoding mRNA [132]. Having observed that DHA reduced COX-2 steady-state mRNA levels at Northern analysis, in the attempt to understand the site of DHA interference we first explored the possibility that DHA might increase COX-2 mRNA stability, setting up experiments to measure the messenger half-life in the presence of actinomycin-D as a transcription blocker. We observed no changes in COX-2 mRNA half-life when the endothelium was exposed to DHA, thus inferring a transcriptional effect for DHA. Accordingly, transient transfection experiments using full-length human COX-2 promoter constructs showed that DHA inhibited total promoter activity independent of the pro-inflammatory stimuli used. Furthermore, by the use of COX-2 promoter constructs either deleted or site-mutated at specific transcriptionally active sites, we observed that DHA inhibitory effect was abrogated only when promoter sequences were lacking, by deletion or site-mutation, functional NF-κB sites. This, together with the observed reduced activation of NF-κB (as assessed by electrophoretic mobility shift assay; EMSA) and the reduced nuclear translocation of p65, suggested an interference by DHA with the activated cytoplasmic signaling pathway leading to NF-κB activation.

It is well known that omega-3 fatty acids, modifying lipid composition, alter membrane lipid microdomains, such as lipid rafts and caveolae, involved in the compartmentalization, modulation, and integration of cell signaling components [133, 134]. In our experimental conditions, DHA accumulates into membrane phospholipids. Therefore, in the attempt to explore which molecular target(s) upstream of NF-κB was (were) affected by DHA, we first focused our attention on the NADPH oxidase, an enzyme system producing ROS involved in the activation of NF-κB by IL-1 [135], the assembly and activation of which is potentially sensitive to membrane phospholipid composition [136]. In resting conditions (fig. 8a), the NADPH oxidase complex consists of several subunits: two of them, p22phox (phox stands for phagocytic oxidase) and glycoprotein (gp)91phox (NOX2 – NOX stands for NADPH oxidase – in the endothelium), are integral membrane proteins, while the p47phox and p67phox subunits are located in the cytosol. Upon cell stimulation (fig. 8b), p47phox is phosphorylated and, in complex with p67phox and the small GTP-binding protein Rac, moves to the plasma mem-

![Fig. 9. DHA reduces COX-2 expression by inhibiting NADPH oxidase and PKCe activation. A The immunocytochemical analysis of the effect of docosahexaenoic acid (DHA) on the stimulated expression of cyclo-oxygenase (COX)-2 in endothelial cells. Human saphenous vein endothelial cells (HSVEC) were grown in 24-well plates for 20 h, and treated with 25 μmol/l DHA for 48 h before stimulation with IL-1α 10 ng/ml for 16 h. After incubations, monolayers were fixed and immunostained with anti-COX-2 monoclonal antibodies. Immunocytochemistry with a non-immune IgG, as a control, revealed no staining (not shown). A reduction of COX-2 expression occurs in cells pre-exposed to DHA (right column). B HSVEC were pretreated with 25 μmol/l DHA for 48 h and then stimulated with 10 ng/ml IL-1α for 1 h. Monolayers were then washed and loaded for 30 min with reduced 2,7’-dichlorodihydrofluorescein diacetate (DCF). This is a non-polar compound that readily diffuses into the cells, where it is hydrolyzed by intracellular esterases to the nonfluorescent derivative, which being polar is trapped within the cells. In the presence of intracellular hydrogen peroxide (H₂O₂) or some of its downstream products, this compound is oxidized to the highly fluorescent compound 2,7’-dichlorofluorescein. The green fluorescence measured is therefore proportional to the H₂O₂ produced. DHA treatment reduces the fluorescence intensity and therefore, by inference, the production of reactive oxygen species (panel in the right column). C HSVEC were pretreated with 25 μmol/l DHA for 48 h and then stimulated with 10 ng/ml IL-1α for 20 min. Subcellular soluble and particulate (membrane) fractions were isolated and Western blots were performed with an antibody specific for p47phox. Values are in units of optical density (OD). The blot depicted is representative of 2 similar ones. D HSVEC were pretreated with 25 μmol/l DHA for 48 h and then stimulated with 10 ng/ml IL-1α for 20 min. Subcellular soluble and particulate (membrane) fractions were isolated and Western blots were performed using anti-PKCε antibody. Values of PKCε translocations are reported as units of OD at densitometric analysis. The blot is representative of 2 similar ones. Modified from Massaro et al. [131].

Nutrigenomics of Omega–3 Fatty Acids

J Nutrigenet Nutrigenomics 2008;1:4–23

17
brane to form the active enzyme complex [137]. We demonstrated that DHA leads to decreased p47phox membrane translocation, together with diminished NAD(P)H oxidase activity and intracellular ROS production (fig. 9b, c). Since PKCs, besides being implicated in NADPH oxidase activation, also mediate COX-2 expression [138], and since PKCε activity is specifically involved in the activation of NF-κB by ERK1/2 induction [139], we next explored the possibility that PKCs could be another molecular switch affected by DHA. We monitored membrane translocation of the main PKC isoforms in endothelial cells stimulated by PMA and IL-1 in the presence of DHA. All such isoforms were activated by PMA, as demonstrated by their translocation to plasma membrane, but only the translocation of PKCε was reduced by DHA treatment (fig. 8d). We therefore concluded that DHA, possibly modifying the plasma membrane lipid composition and hence membrane microdomain organization, inhibits at least two molecular switches both involved in COX-2 expression, the activation of NAD(P)H oxidase and the activation of PKCε. An integrative molecular model of dietary omega-3 fatty acids interference with IL-1 signaling pathway leading to adhesion molecules and COX-2 induction in endothelial cells is proposed in figure 10.

**Conclusions and Perspectives**

The vascular endothelium plays a key role in the progression of cardiovascular disease as well as in the maintenance of solid cancer cell cords, orchestrating the neo-vascularization of atherosclerotic plaque and cancer tissue growth. On the other hand, omega-3 fatty acids have emerged as an effective tool in the primary and secondary prevention of cardiovascular disease and some forms of cancer. Although they exert multiple actions [140], the transcriptional control of several endothelial pro-inflammatory genes, including those encoding for adhesion molecules, chemokines and other soluble cytokines in the endothelium, likely play an important role. The recent findings showing inhibition of COX-2 expression and activity by omega-3 fatty acids allows a deeper understanding of the therapeutic potential of these nutrients, being COX-2 overexpression pathogenetically involved in different inflammatory/degenerative diseases besides atherosclerosis (from rheumatoid arthritis to inflammatory bowel disease and, possibly, Alzheimer's disease). Far from being therefore only a source of energy and building blocks of our body tissues, omega-3 fatty acids appear therefore to finely tune the response of our genes to dangerous environmental challenges, by curbing physiological responses without abrogating them totally. By decreasing the endothelial responsiveness to pro-inflammatory,
pro-atherogenic and pro-angiogenic stimuli, omega-3 fatty acids appear to impact molecular events not targeted by any other drugs or interventions, thus allowing us to propose their therapeutic role complementary to those of already implemented pharmacologic treatments in inflammatory diseases, including atherosclerosis. These are clear examples of nutrigenomics, i.e., how selected nutrients may affect the expression of our genes, allowing the interaction of genes with the environment in modulating the risk of human diseases.

Acknowledgements

We are indebted to all our former and current collaborators at the Laboratory for Thrombosis and Vascular Research at the Institute of Clinical Physiology of the Italian National Research Council (Consiglio Nazionale delle Ricerche, CNR) in Pisa, the Laboratory for Atherosclerosis Research at the CNR Institute of Clinical Physiology in Lecce, the Experimental Cardiology Laboratory at the ‘G. d’Annunzio’ Foundation in Chieti and the Laboratory of General Physiology at the University of Lecce for the experimental data on which most of the considerations here highlighted are based. We are also indebted to Peter Libby, MD, in whose laboratory the first observations of the nutrigenomic effects of DHA were made.

References


28 Leahy K, Koki A, Masferrer J: Role of cyclo-
29 oxygenase in angiogenesis. Curr Med Chem

30 Smith WL, Garavito RM, DeWitt DL: Pros-
31 taglandin endoperoxide H synthases (cyclo-
33 3157–33160.

31 Liu XH, Kirschenbaum A, Lu M, Yao S, Do-
32 sorezt A, Holland JF, Levine AC: Prostaglan-
33 din E2 induces hypoxia-inducible factor-1al-
34 pha stabilization and nuclear localization in
35 a human prostate cancer cell line. J Biol Chem
36 2002;277:50081–50086.

32 Hahn GL, Polgar PG: Prostaglandin produc-
33 tion in phenotypically distinct cultured bo-
34 vine pulmonary artery endothelium. Ath-
35 hophysiology 1984;51:143–150.

34 Leahy K, Koki A, Masferrer J: Role of cyclo-
35 oxygenase-2 in angiogenesis. Curr Med Chem

36 Smith WL, Garavito RM, DeWitt DL: Pros-
37 taglandin endoperoxide H synthases (cyclo-
38 oxygenases)-1 and -2. J Biol Chem 1996;271:
39 3157–33160.

37 Liu XH, Kirschenbaum A, Lu M, Yao S, Do-
38 sorezt A, Holland JF, Levine AC: Prostaglan-
39 din E2 induces hypoxia-inducible factor-1al-
40 pha stabilization and nuclear localization in
41 a human prostate cancer cell line. J Biol Chem
42 2002;277:50081–50086.

42 Dormond O, Berzi M, Mariotti A, Ruegg C:
43 Prostaglandin E2 promotes integrin alpha
44 Vbeta 3-dependent endothelial cell adhe-
45 sion, rac-activation, and spreading through
cAMP/PKA-dependent signaling. J Biol Chem
46 2002;277:45838–45846.

43 Dormond O, Foletti A, Paroz C, Ruegg C:
44 NSAIDs inhibit alpha V beta 3 integrin-me-
45 diated and Cdc42/Rac-dependent endothel-
46 ial-cell spreading, migration and angiogen-

44 Pai R, Soreghan B, Szabo IL, Pavelka M, Ba-
45 tar J, Tarnawski AS: Prostaglandin E2 tran-
46 sactivates EGF receptor: A novel mecha-
47 nism for promoting colon cancer growth and
gastrointestinal hypertrophy. Nat Med 2002;
48 8:289–293.

45 Schwacha MG, Chung CS, Ayala A, Bland
46 KI, Chaudry IH: Cyclooxygenase-2 mediated
47 suppression of macrophage interleukin-12
48 production after thermal injury. Am J
49 Physiol 2002;282:C263–C270.

46 Schönbeck U, Sukkova G, Gruber F, Cou-
47 lents A, Libby P: Augmented expression of cy-
48 clooxygenase-2 in human atherosclerotic le-

50 Stemme V, Swedenborg J, Claesson H, Hans-
51 son GK: Expression of cyclooxygenase-2 in
52 human atherosclerotic lesions. J Biol Chem
53 2002;277:27613–27621.

51 Dimmel S, Zeiher AM: Akt takes center stage
52 in angiogenesis signaling. Circ Res

52 Callejas N, Casado M, Diaz-Guerra M, Bosca
53 L, Martin-Sanz P: Expression of cyclooxy-
54 genase-2 promotes the release of matrix me-
55 talloproteinase-2 and -9 in fetal rat hepatocytes.

53 Choi YA, Lee DJ, Lim HK, Jeong JH, Son J,
54 Kang SS, Raek SH: Interleukin-1beta stimu-
55 lates matrix metalloproteinase-2 expression
56 via a prostaglandin E2-dependent mecha-
57 nism in human chondrocytes. Exp Mol Med

54 Pavlovic S, Du B, Sakamoto K, Khan KM,
55 Natarajan C, Breyer RM, Dannenberg AJ,
56 Falcone DJ: Targeting prostaglandin E2 re-
57 ceptors as an alternative strategy to block
cyclooxygenase-2-dependent extracellular
58 matrix-induced matrix metalloproteinase-9
59 expression by macrophages. J Biol Chem
60 2006;281:3321–3328.

60 Dornow GW 2nd, Becker MW, Davis MG: Dis-
61 sociation of the contractile and hypertrophic
62 effects of vasoconstrictor prostanooids in vas-
63 cular smooth muscle. J Biol Chem 1992;267:
64 24897–24905.

62 Okon EB, Szado T, Laerer I, McManus B, van
63 Bremen C: Augmented contractile response
64 of vascular smooth muscle in a diabetic mouse

63 Wohlfel ER, Campbell WB: 25-Hydroxy-
64 cholestrol increases eicosanoids and alters
65 morphology in cultured pulmonary artery
66 smooth muscle and endothelial cells. Ar-
68 2908.

64 Wong ST, Baker LP, Trinh K, Hetman M, Su-
69 zuki LA, Storm DR, Bornfeldt KE: Adenylcycl
70 e 3 mediates prostaglandin E2-in-
71 duced growth inhibition in arterial smooth
73 34212.

65 Huettner JG, Gweby ET, Panganamala RV,
66 Milo GE, Cornell DC, Sharma HM, Geer
67 JC: Fatty acids and their prostaglandin deriv-
68 atives: Inhibitors of proliferation in aortic
69 smooth muscle cells. Science 1977;197:289–
70 291.

66 Cipollone F and Fazia ML: COX-2 and ath-
70 rosclerosis. J Cardiovasc Pharmacol 2006;
71 47(suppl 1):S26–S36.

67 Stacy ZA, Dobesh PP, Trujillo TC: Cardio-
71 vascular risks of cyclooxygenase inhibition.
72 Pharmacotherapy 2006;26:919–938.

68 Bea F, Blessing E, Bennett BJ, Kuoc CC, Camp-
72 bell J, Kreuzer J, Rosenfeld ME: Chronic
73 inhibition of cyclooxygenase-2 does not alter
74 plaque composition in a mouse model of ad-
75 vanced unstable atherosclerosis. Cardiovasc
76 Res 2003;60:198–204.

69 Burleigh ME, Babaev VR, Oates JA, Harris
70 RC, Gautam S, Rendue D, Marnett LJ,
71 Morrow JD, Fazio S, Linton MF: Cyclooxy-
72 genase-2 promotes early atherosclerotic le-
73 sion formation in LDL receptor-deficient

70 Burleigh ME, Babaev VR, Yancey CG, Major
71 AS, McCaleb JL, Oates JA, Morrow JD, Fazio
72 S, Linton MF: Cyclooxygenase-2 promotes early

72 Pratico D, Tillmann C, Zhang ZB, Li H, Fitz-
73 gerald GA: Acceleration of atherogene-
74 sis by COX-1-dependent prostanooid forma-
75 tion in low density lipoprotein receptor
76 knockout mice. Proc Natl Acad Sci USA

73 Rott D, Zhu J, Burnett MS, Zhou YF, Zalles-
74 Ganley A, Ogumnakina J, Epstein SE:
75 Effects of MF-tricyclic, a selective cyclooxy-
76 genase-2 inhibitor, on atherosclerosis pro-
77 gression and susceptibility to cytomaglovi-
78 rus replication in apoliprotein E-knockout
Nutrigenomics of Omega-3 Fatty Acids

J Nutrigenet Nutrigenomics 2008;1:4–23


Massaro/Scoditti/Carluccio/Montinari/ De Caterina


